SCHEMBL16985241

SCHEMBL16985241

CS(=O)(=O)c1cc2ccccc2o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.67
CCR2 P41597 5/20 0.54
AKR1B1 P15121 2/20 0.50
CA9 Q16790 3/20 0.47
CA1 P00915 2/20 0.47
CA12 O43570 2/20 0.47
FLT3 P36888 1/20 0.46
CYP2A6 P11509 1/20 0.46
TYR P14679 1/20 0.44
DAO P14920 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MAOB P27338 3/20 0.43
MAOA P21397 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19258581 0.83 CA2 (0.60) CA2CCR2AKR1B1CA9CA1
SCHEMBL7137894 0.83 CA2 (0.71) CA2CCR2AKR1B1CA9CA1
SCHEMBL329665 0.82 CA2 (0.69) CA2CCR2AKR1B1CA9CA1
SCHEMBL18184669 0.81 CA2 (0.62) CA2CCR2AKR1B1CA9CA1
SCHEMBL1655317 0.80 CA2 (0.67) CA2CCR2AKR1B1CA9CA1
SCHEMBL9063028 0.80 CA2 (0.67) CA2CCR2AKR1B1CA9CA1
SCHEMBL31695410 0.80 CA2 (0.67) CA2CCR2AKR1B1CA9CA1
SCHEMBL1156380 0.80 CA2 (1.00) CA2AKR1B1CA9CA1CA12
SCHEMBL720789 0.80 CA2 (0.67) CA2CCR2AKR1B1CA9CA1
SCHEMBL29926951 0.80 CA2 (1.00) CA2AKR1B1CA9CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 US disclosed
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME EA PHARMA CO., LTD. (JP) 2018-06-14 US disclosed
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME EA PHARMA CO., LTD. (JP) 2018-06-14 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
WO-2015115507-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME 味の素株式会社 2015-08-06 WO disclosed
CN-100335136-C Pharmaceutical composition with reduced tendency for crystallization of drug PHARMACIA CORP (US) 2007-09-05 CN disclosed
CN-1498114-A Pharmaceutical composition with reduced tendency for crystallization of drug 2004-05-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 CA2 210/4885CCR2 615/4885AKR1B1 1066/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 CA2 210/4885CCR2 615/4885AKR1B1 1066/4885
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME TRPA1, TRPV1, TRPV2 CA2 834/4885CCR2 444/4885AKR1B1 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.